B+
Bull case
25%
Probability
Target price
$5.00
+46.2% vs current
FBIO
Fortress BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.65
+6.7% vs current
B-
Bear case
25%
Probability
Target price
$2.30
-32.7% vs current
AI sentiment snapshot
Latest data as of 2026-07-19
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+62.0
Score
AI commentary
Primary-source tone is constructive around ZYCUBO approval, PRV monetization, debt reduction, and royalty optionality [#SEC-8K-2026-05-14]. However, headline flow is thin, analyst revisions are unavailable, direct peer comparisons are unreliable, social coverage is absent, and there are no confirmed near-term dated catalysts; this remains a low-conviction monitoring setup.
RankAlpha Sentiment Codex - 2026-07-19
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-17eventPartnered regulatory progress for anselamimabHigh impact
Management highlighted AstraZeneca regulatory submissions in the EU and Japan for anselamimab, creating potential future approval and sales-milestone optionality, although timing and outcomes remain uncertain [#SEC-8K-2026-05-14].
2026-10-17catalystPost-monetization balance-sheet and royalty conversionHigh impact
Q1 materials reported $108.4 million of net income, the $205 million PRV sale, and Oaktree principal reduced to $15 million. Near-term upside depends on whether the one-time cash benefit translates into recurring royalty and milestone visibility [#SEC-8K-2026-05-14].
2027-07-19catalystRoyalty and portfolio maturationHigh impact
Fortress expects increasing royalty revenue from ZYCUBO and UNLOXCYT and retains equity and a 3% royalty exposure to dotinurad following its progression into Phase 3. This supports longer-duration upside if partners execute [#SEC-8K-2026-05-14] [#SEC-8K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-19 • Updated nightlySource: Internal modelMethodology